https://www.selleckchem.com/products/CHIR-258.html
001) , and receiving imatinib as front-line therapy (P less then 0.001) significantly increased with age. No significant differences in gender and the EUTOS Long-Term Survival risks were noted across the three age groups. The multivariate analysis showed that ≥60 years was an adverse predictor for overall survival. However, age was not significantly associated with tyrosine kinase inhibitor (TKI) therapy responses and other outcomes. The incidences of nonhematological toxicity were significantly increased with age during TKI therapy (P
Curtir
Comentario
Compartilhar
